[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[3]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[4]
|
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W.G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D. and ESMO-ESGO Ovarian Cancer Consensus Conference Working Group (2019) ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Annals of Oncology, 30, 672-705. https://doi.org/10.1093/annonc/mdz062
|
[5]
|
Delgado Bolton, R.C., Aide, N., Colletti, P.M., Ferrero, A., Paez, D., Skanjeti, A. and Giammarile, F. (2021) EANM Guideline on the Role of 2-[18F]FDG PET/CT in Diagnosis, Staging, Prognostic Value, Therapy Assessment and Restaging of Ovarian Cancer, Endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). European Journal of Nuclear Medicine and Molecular Imaging, 48, 3286-3302. https://doi.org/10.1007/s00259-021-05450-9
|
[6]
|
Gadducci, A., Simonetti, E., Guidoccio, F., Manca, G., Giorgetti, A., Depalo, T., Cosio, S., Miccoli, M. and Volterrani, D. (2021) Have Volume-Based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients with Potentially Platinum-Responsive Recurrent Ovarian Cancer? A Single Center Italian Study. Anticancer Research, 41, 1937-1944. https://doi.org/10.21873/anticanres.14960
|
[7]
|
Wang, Q.Y., Feng, X.L., Liu, X.F. and Zhu, S.Y. (2022) Prognostic Value of Elevated Pre-Treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. Frontiers in Oncology, 12, Article 868061. https://doi.org/10.3389/fonc.2022.868061
|
[8]
|
Chan, J.K., Tian, C., Kesterson, J.P., Richardson, M.T., Lin, K., Tewari, K.S., Herzog, T., Kapp, D.S., Monk, B.J., Casablanca, Y., Hanjani, P., Wenham, R.M., Walker, J., McNally, L., Copeland, L.J., Robertson, S., Lentz, S., Spirtos, N.M. and Bell, J.G. (2022) The Clinical and Prognostic Significance of Pre-Chemotherapy Serum CA-125 in High-Risk Early Stage Ovarian Cancer: An NRG/GOG Ancillary Study. Gynecologic Oncology, 167, 429-435. https://doi.org/10.1016/j.ygyno.2022.09.028
|
[9]
|
Timmermans, M., Zwakman, N., Sonke, G.S., Van de Vijver, K.K., Duk, M.J., van der Aa, M.A. and Kruitwagen, R.F. (2019) Perioperative Change in CA125 Is an Independent Prognostic Factor for Improved Clinical Outcome in Advanced Ovarian Cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology, 240, 364-369. https://doi.org/10.1016/j.ejogrb.2019.07.010
|
[10]
|
Liao, Y.C., Ou, Y.C., Wu, C.H., Fu, H.C., Tsai, C.C. and Lin, H. (2021) CA125 Normalization within 60 Days as an Independent Prognostic Factor for Patients with Advanced Epithelial Ovarian Cancer. Cancer Biomarkers, 32, 559-567. https://doi.org/10.3233/CBM-210156
|
[11]
|
Li, Z., Yin, H., Ren, M. and Shen, Y. (2020) Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma. Medical Science Monitor, 26, e925051. https://doi.org/10.12659/MSM.925051
|
[12]
|
Kim, B., Park, Y., Kim, B., Ahn, H.J., Lee, K.A., Chung, J.E. and Han, S.W. (2019) Diagnostic Performance of CA 125, HE4, and Risk of Ovarian Malignancy Algorithm for Ovarian Cancer. Journal of Clinical Laboratory Analysis, 33, e22624. https://doi.org/10.1002/jcla.22624
|
[13]
|
Sun, M.L., Yang, Z.Y., Wu, Q.J., Li, Y.Z., Li, X.Y., Liu, F.H., Wei, Y.F., Wen, Z.Y., Lin, B. and Gong, T.T. (2022) The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. Frontiers in Medicine, 9, Article 842002. https://doi.org/10.3389/fmed.2022.842002
|
[14]
|
Lee, S., Choi, S., Lee, Y., Chung, D., Hong, S. and Park, N. (2017) Role of Human Epididymis Protein 4 in Chemoresistance and Prognosis of Epithelial Ovarian Cancer. Journal of Obstetrics and Gynaecology Research, 43, 220-227. https://doi.org/10.1111/jog.13181
|
[15]
|
Salminen, L., Gidwani, K., Grenman, S., Carpen, O., Hietanen, S., Pettersson, K., Huhtinen, K. and Hynninen, J. (2020) HE4 in the Evaluation of Tumor Load and Prognostic Stratification of High Grade Serous Ovarian Carcinoma. Acta Oncologica, 59, 1461-1468. https://doi.org/10.1080/0284186X.2020.1827157
|
[16]
|
Furrer, D., Gregoire, J., Turcotte, S., Plante, M., Bachvarov, D., Trudel, D., Tetu, B., Douville, P. and Bairati, I. (2019) Performance of Preoperative Plasma Tumor Markers HE4 and CA125 in Predicting Ovarian Cancer Mortality in Women with Epithelial Ovarian Cancer. PLOS ONE, 14, e0218621. https://doi.org/10.1371/journal.pone.0218621
|
[17]
|
Ghafouri-Fard, S., Shoorei, H. and Taheri, M. (2020) MiRNA Profile in Ovarian Cancer. Experimental and Molecular Pathology, 113, Article ID: 104381. https://doi.org/10.1016/j.yexmp.2020.104381
|
[18]
|
Aboutalebi, H., Bahrami, A., Soleimani, A., Saeedi, N., Rahmani, F., Khazaei, M., Fiuji, H., Shafiee, M., Ferns, G.A., Avan, A. and Hassanian, S.M. (2020) The Diagnostic, Prognostic and Therapeutic Potential of Circulating MicroRNAs in Ovarian Cancer. The International Journal of Biochemistry & Cell Biology, 124, Article ID: 105765. https://doi.org/10.1016/j.biocel.2020.105765
|
[19]
|
Davies, M., Davey, M.G. and Miller, N. (2022) The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment. Genes (Basel), 13, Article 2054. https://doi.org/10.3390/genes13112054
|
[20]
|
Yunusova, N., Dzhugashvili, E., Yalovaya, A., Kolomiets, L., Shefer, A., Grigor’eva, A., Tupikin, A., Kondakova, I. and Tamkovich, S. (2022) Comparative Analysis of Tumor-Associated MicroRNAs and Tetraspanines from Exosomes of Plasma and Ascitic Fluids of Ovarian Cancer Patients. International Journal of Molecular Sciences, 24, Article 464. https://doi.org/10.3390/ijms24010464
|
[21]
|
Zhao, L., Liang, X., Wang, L. and Zhang, X. (2022) The Role of MiRNA in Ovarian Cancer: An Overview. Reproductive Sciences, 29, 2760-2767. https://doi.org/10.1007/s43032-021-00717-w
|
[22]
|
Yoshida, K., Yokoi, A., Matsuzaki, J., Kato, T., Ochiya, T., Kajiyama, H. and Yamamoto, Y. (2021) Extracellular MicroRNA Profiling for Prognostic Prediction in Patients with High-Grade Serous Ovarian Carcinoma. Cancer Science, 112, 4977-4986. https://doi.org/10.1111/cas.15154
|
[23]
|
Suzuki, K., Yokoi, A., Yoshida, K., Kato, T., Ochiya, T., Yamamoto, Y. and Kajiyama, H. (2022) Preoperative Serum MicroRNAs as Potential Prognostic Biomarkers in Ovarian Clear Cell Carcinoma. Journal of Gynecologic Oncology, 34, e34.
|
[24]
|
Noguchi, T., Iwahashi, N., Sakai, K., Matsuda, K., Matsukawa, H., Toujima, S., Nishio, K. and Ino, K. (2020) Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact. Cancers (Basel), 12, Article 3382. https://doi.org/10.3390/cancers12113382
|
[25]
|
Lu, Y. and Li, L. (2021) The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis. Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177/15330338211043784
|
[26]
|
Hou, J.Y., Chapman, J.S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R.M., Ross, A., Mills, M., Suarez, C.J., Davis, T., Edwards, R., Boisen, M., Sawyer, S., Wu, H.T., Dashner, S., Aushev, V.N., George, G.V., Malhotra, M., Zimmermann, B., Sethi, H., ElNaggar, A.C., Aleshin, A. and Ford, J.M. (2022) Circulating Tumor DNA Monitoring for Early Recurrence Detection in Epithelial Ovarian Cancer. Gynecologic Oncology, 167, 334-341. https://doi.org/10.1016/j.ygyno.2022.09.004
|
[27]
|
Chao, A., Chen, S.J., Chen, H.C., Tan, K.T., Hsiao, W., Jung, S.M., Yang, L.Y., Huang, K.G., Chou, H.H., Huang, H.J., Chang, T.C., Chao, A.S., Lee, Y.H., Wu, R.C. and Lai, C.H. (2022) Mutations in Circulating Tumor DNA Detected in the Postoperative Period Predict Poor Survival in Patients with Ovarian Cancer. Biomedical Journal. https://doi.org/10.1016/j.bj.2022.09.004
|
[28]
|
Qiu, J.J., Lin, X.J., Zheng, T.T., Tang, X.Y. and Hua, K.Q. (2018) Natural Antisense Transcript of Hypoxia-Inducible Factor 1 Regulates Hypoxic Cell Apoptosis in Epithelial Ovarian Cancer. OncoTargets and Therapy, 11, 9101-9110. https://doi.org/10.2147/OTT.S173816
|
[29]
|
Tang, X., Liu, S., Liu, Y., Lin, X., Zheng, T., Liu, X., Qiu, J. and Hua, K. (2019) Circulating Serum Exosomal aHIF Is a Novel Prognostic Predictor for Epithelial Ovarian Cancer. OncoTargets and Therapy, 12, 7699-7711. https://doi.org/10.2147/OTT.S220533
|
[30]
|
Rong, Y. and Li, L. (2021) Early Clearance of Serum HE4 and CA125 in Predicting Platinum Sensitivity and Prognosis in Epithelial Ovarian Cancer. Journal of Ovarian Research, 14, Article No. 2. https://doi.org/10.1186/s13048-020-00759-9
|
[31]
|
Nie, X.C., He, F., Lan, C., Niu, J.M. and Xia, P. (2021) Combined Serum DKK3 and Circulating CD133 Cells as Prognostic Biomarkers for Ovarian Cancer Patients. OncoTargets and Therapy, 14, 427-434. https://doi.org/10.2147/OTT.S288191
|
[32]
|
Ye, S., Liu, S., Zhou, S., Xiang, L., Wu, X. and Yang, H. (2020) The Role of 18F-FDG PET/CT-Based Quantitative Metabolic Parameters in Patients with Ovarian Clear Cell Carcinoma. Cancer Biomarkers, 27, 189-194. https://doi.org/10.3233/CBM-190904
|
[33]
|
Yamamoto, M., Tsujikawa, T., Fujita, Y., Chino, Y., Kurokawa, T., Kiyono, Y., Okazawa, H. and Yoshida, Y. (2016) Metabolic Tumor Burden Predicts Prognosis of Ovarian Cancer Patients Who Receive Platinum-Based Adjuvant Chemotherapy. Cancer Science, 107, 478-485. https://doi.org/10.1111/cas.12890
|
[34]
|
Kim, C.Y., Jeong, S.Y., Chong, G.O., Son, S.H., Jung, J.H., Kim, D.H., Lee, S.W., Ahn, B.C. and Lee, J. (2015) Quantitative Metabolic Parameters Measured on F-18 FDG PET/CT Predict Survival after Relapse in Patients with Relapsed Epithelial Ovarian Cancer. Gynecologic Oncology, 136, 498-504. https://doi.org/10.1016/j.ygyno.2014.12.032
|
[35]
|
Ye, S., Liu, S., Xiang, L., Wu, X. and Yang, H. (2019) 18F-FDG PET/CT-Based Metabolic Metrics in Recurrent Tumors of Ovarian Clear Cell Carcinoma and Their Prognostic Implications. BMC Cancer, 19, Article No. 226. https://doi.org/10.1186/s12885-019-5441-7
|
[36]
|
Vallius, T., Hynninen, J., Kemppainen, J., Alves, V., Auranen, K., Matomaki, J., Oksa, S., Virtanen, J., Grenman, S., Auranen, A. and Seppanen, M. (2018) 18F-FDG-PET/CT Based Total Metabolic Tumor Volume Change during Neoadjuvant Chemotherapy Predicts Outcome in Advanced Epithelial Ovarian Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 45, 1224-1232. https://doi.org/10.1007/s00259-018-3961-z
|
[37]
|
Sun, J., Cui, X.W., Li, Y.S., Wang, S.Y., Yin, Q., Wang, X.N. and Gu, L. (2020) The Value of 18F-FDG PET/CT Imaging Combined with Detection of CA125 and HE4 in the Diagnosis of Recurrence and Metastasis of Ovarian Cancer. European Review for Medical and Pharmacological Sciences, 24, 7276-7283.
|
[38]
|
Glickman, A., Paredes, P., Carreras-Diéguez, N., Ninerola-Baizán, A., Gaba, L., Pahisa, J., Fusté, P., Del Pino, M., Díaz-Feijóo, B., González-Bosquet, E., Agustí, N., Sánchez-Izquierdo, N., Fuster, D., Perissinotti, A., Romero, I., Fernández-Galán, E., Carrasco, J.L., Gil-Ibánez, B. and Torné, A. (2022) Evaluation of Patients with Advanced Epithelial Ovarian Cancer before Primary Treatment: Correlation between Tumour Burden Assessed by [18F]FDG PET/CT Volumetric Parameters and Tumour Markers HE4 and CA125. European Radiology, 32, 2200-2208. https://doi.org/10.1007/s00330-021-08305-x
|
[39]
|
Budak, A., Budak, E., Inan, A., Kanmaz, A., Tosun, G., Beyan, E., Aldemir, O., Ileri, A. and Ozeren, M. (2021) The Value of Posttreatment CA125 and PET/CT in Predicting Prognosis of Epithelial Ovarian Cancer. Annals of Medical Research, 28, 1961-1966. https://doi.org/10.5455/annalsmedres.2020.11.1150
|